Skip to content
Study details
Enrolling now

Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases

Ayal A. Aizer, MD
NCT IDNCT07130786ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

150

Study length

about 4.4 years

Ages

18+

Locations

1 site in MA

What this study is about

This trial is testing whether prophylactic levetiracetam (Keppra) reduces seizures in adults with brain metastases located in the primary motor cortex. Participants will be randomly assigned to receive either levetiracetam or standard care, which does not include levetiracetam.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Levetiracetam (Keppra)

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized (Open Label)

You are randomly assigned, but you will know your treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

levetiracetam

Drug routes

oral (Oral Tablet)

Endpoints

Secondary: Overall survival, Performance status, Progression free survival, Quality of life/symptom burden and interference

Body systems

Neurology